Zeripatamig is under clinical development by Light Chain Bioscience and currently in Phase I for Marginal Zone B-cell Lymphoma. According to GlobalData, Phase I drugs for Marginal Zone B-cell Lymphoma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Zeripatamig’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zeripatamig overview

Zeripatamig is under development for the treatment of  acute lymphocytic leukemia (ALL), B-cell non-Hodgkin lymphoma (NHL) including Richter's transformation, marginal zone B-cell lymphoma, diffuse large b-cell lymphoma, mantle cell lymphoma, follicular lymphoma, chronic lymphocytic leukemia (CLL), and unspecified B-cell lymphoma. It is administered through oral route. The drug candidate is a bi-specific monoclonal antibody, which acts by targeting CD47 and CD19. It is developed based on Kappa Lambda Body technology.

It was also under development for the treatment of diffuse large B-cell lymphoma and melanoma.

Light Chain Bioscience overview

Light Chain Bioscience (Light Chain), formerly NovImmune, is a biopharmaceutical company that discovers and develops antibody-based drugs for the treatment of inflammatory diseases, immune-related disorders and cancer. The company’s pipeline products include NI-0101, a toll-like receptor 4 monoclonal antibody for the treatment of chronic inflammation; NI-0401 a monoclonal antibody that targets CD3-epsilon, molecule that sits on the surface of a white blood cell; Emapalumab (NI-0501), a human anti-IFNy monoclonal antibody used for the treatment of hemophagocytic lymphohistiocytosis. It also develops NI-1201, an anti-IL6R monoclonal antibody to treat immune disorders; NI-1401, an Interleukin-17 monoclonal antibody used for the treatment of autoimmune and inflammatory diseases; NI-1701, an anti-CD19/anti-CD47 bispecific antibody that kills tumor cell; and NI-1801 an anti-CD47 that binds mesothelin-positive solid tumors. The company develops pipeline products using its proprietary bispecific antibody and bispecific antibody platform. Light Chain is headquartered in Geneva, Switzerland.

For a complete picture of Zeripatamig’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.